RedHill acquired the exclusive worldwide rights to RHB-107, excluding China, Hong Kong, Taiwan and Macao, from Germany's ...

The FDA approved the PD-1 inhibitor penpulimab, with two indications, for treating non-keratinizing nasopharyngeal carcinoma ...

Barred from running for office until 2030 and facing the possibility of decades in prison, Brazil’s former president sketches ...

KENNEDY, in interview with Sean Hannity that aired on Fox News on March 11: “There are adverse events from the vaccine. It ...

"There was no way I was having that conversation with her, so I feigned stupidity and said it was outside my knowledge area." ...

Over 800 cases of measles and three deaths from the disease have been reported this year, according to the CDC, and experts ...

"Vaccination rates have declined nationwide since the COVID-19 pandemic ... spreading downward to the neck, trunk, arms, legs and feet. When the rash appears, the fever may spike over 104 degrees ...

For combination therapy, the FDA recommends 200 mg of penpulimab-kcqx every 3 weeks. Monotherapy is recommended at 200 mg ...

We want you to take advantage of everything Cancer Therapy Advisor has to offer. To view unlimited content, log in or register for free.

With one-fifth of states seeing active measles outbreaks, the U.S. is nearing 900 cases, according to figures posted Friday by the U.S. Centers for Disease Control and Prevention.

Penpulimab-kcqx, a humanized immunoglobulin G1 monoclonal antibody, blocks the interaction between the programmed death 1 receptor on T-cells and programmed death ligand 1 and 2 on tumor cells.